Technical Analysis for CELG - Celgene Corporation

Grade Last Price % Change Price Change
grade B 127.65 0.05% 0.07
CELG closed up 0.05 percent on Friday, August 18, 2017, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Down Down
See historical CELG trend table...

Date Alert Name Type % Chg
Aug 18 New Downtrend Bearish 0.00%
Aug 18 Lower Bollinger Band Walk Other 0.00%
Aug 17 Stochastic Reached Oversold Other 0.05%
Aug 16 Fell Below 50 DMA Bearish -2.75%
Aug 16 MACD Bearish Centerline Cross Bearish -2.75%

Older signals for CELG ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Its commercial stage products include REVLIMID, a drug to treat multiple myeloma and transfusion-dependent anemia; VIDAZA, a nucleoside analog to treat intermediate-2 and myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML); ABRAXANE, a chemotherapy treatment option for metastatic breast cancer; and THALOMID for multiple myeloma and the cutaneous manifestations of erythema nodosum leprosum. The company's commercial stage products also comprise ISTODAX to treat cutaneous T-cell lymphoma; POMALYST for the multiple myeloma and myelofibrosis treatment; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its pre clinical and clinical stage products consist of CC-11050, an anti-inflammatory compound; CC-220, an anti-inflammatory product; cellular therapies, such as PDA-001 and PDA-002; CC-486 that is in Phase III trials to treat MDS and AML, as well as in a Phase I trials for solid tumor indications; and sotatercept and ACE-536, which are in Phase II trials to treat anemia. The company's pre clinical and clinical stage products also include CC-223, a dual TORK inhibitor; CC-292, a BTK inhibitor; CC-115, a dual TORK/DNA PK inhibitor; CC-122, a pleiotropic pathway modulator; and EPZ-5676, a DOT1L inhibitor. It has strategic collaborations with bluebird bio, Inc.; FORMA Therapeutics Holdings; Concert Pharmaceuticals, Inc.; Array BioPharma, Inc.; and Acetylon Pharmaceuticals, Inc., as well as a strategic alliance with MorphoSys AG. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Is CELG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 139.0
52 Week Low 96.93
Average Volume 3,995,790
200-Day Moving Average 122.3533
50-Day Moving Average 131.695
20-Day Moving Average 133.901
10-Day Moving Average 131.97
Average True Range 2.5227
ADX 25.06
+DI 16.17
-DI: 28.8
Chandelier Exit (Long, 3 ATRs) 131.4319
Chandelier Exit (Short, 3 ATRs) 134.8381
Upper Bollinger Band 139.9798
Lower Bollinger Band 127.8222
Percent B (%b) -0.01
Bandwidth 0.090795
MACD Line -0.8418
MACD Signal Line 0.2587
MACD Histogram -1.1005